Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613852 | 0.77 | TP53 (0.48) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL3822346 | 0.77 | POLB (0.48) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL8961436 | 0.75 | LMNA (0.48) | CYP2C19 | |
| SCHEMBL10588317 | 0.74 | POLB (0.43) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL8961272 | 0.74 | POLB (0.43) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL7066106 | 0.74 | TP53 (0.50) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL3904945 | 0.74 | POLB (0.50) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL2458189 | 0.74 | TP53 (0.50) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL4462235 | 0.74 | POLB (0.50) | CYP3A4CYP2C9CYP2C19POLBTP53 | |
| SCHEMBL9050380 | 0.73 | POLB (0.46) | CYP3A4CYP2C9CYP2C19POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066575-A1 | Methods and compositions for mitigating pain | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-03-22 | — | — | US | disclosed |
| US-7115661-B1 | Methods and compositions for mitigating pain | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-10-03 | — | — | US | disclosed |
| EP-1518553-A2 | Use of nitrate ester compounds for treating pain or providing analgesia | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-03-30 | — | — | EP | disclosed |
| EP-1246625-B1 | USES AND COMPOSITIONS OF NITRATE ESTERS FOR PROVIDING SEDATION | UNIV KINGSTON (CA) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066575-A1 | Methods and compositions for mitigating pain | NOS2, OPRK1, NOS3 | CYP3A4 129/4885CYP2C9 280/4885CYP2C19 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.